UCB SA Company Insiders
UCBJY Stock | USD 58.22 1.22 2.14% |
UCB SA employs about 8.6 K people. The company is managed by 41 executives with a total tenure of roughly 354 years, averaging almost 8.0 years of service per executive, having 209.76 employees per reported executive. Break down of UCB SA's management performance can provide insight into the company performance.
Gerhard Mayr Chairman Non-Executive Chairman of the Board |
JeanChristophe Tellier Chairman Chairman of the Executive Committee, CEO |
UCB |
UCB SA Management Team Effectiveness
The company has return on total asset (ROA) of 0.0468 % which means that it generated a profit of $0.0468 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1069 %, meaning that it generated $0.1069 on every $100 dollars invested by stockholders. UCB SA's management efficiency ratios could be used to measure how well UCB SA manages its routine affairs as well as how well it operates its assets and liabilities.UCB SA Workforce Comparison
UCB SA ADR is rated first in number of employees category among related companies. The total workforce of Biotechnology industry is at this time estimated at about 114,032. UCB SA holds roughly 8,600 in number of employees claiming about 8% of stocks in Biotechnology industry.
The company has Profit Margin (PM) of 0.15 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.19 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.19. UCB SA ADR Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. UCB SA ADR Price Series Summation is a cross summation of UCB SA price series and its benchmark/peer.
UCB SA Notable Stakeholders
An UCB SA stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as UCB SA often face trade-offs trying to please all of them. UCB SA's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting UCB SA's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Gerhard Mayr | Non-Executive Chairman of the Board | Profile | |
JeanChristophe Tellier | Chairman of the Executive Committee, CEO | Profile | |
Roch Doliveux | Chairman of the Executive Committee, CEO, Executive Director | Profile | |
Pascale Richetta | Executive Vice President Bone Patient Value Unit Head, Member of the Executive Committee | Profile | |
Xavier Michel | Vice President and Secretary General | Profile | |
Dhavalkumar Patel | Executive Vice President Chief Scientific Officer, Member of the Executive Committee | Profile | |
Bharat Tewarie | Executive Vice President Chief Marketing Officer | Profile | |
Jeff Wren | Executive Vice President Neurology – Patient Value Unit Head | Profile | |
Charl Zyl | Executive Vice President Head of Patient Value Operations, Member of the Executive Committee | Profile | |
Fabrice Enderlin | Executive Vice President - Human Resources & Communication, Member of the Executive Committee | Profile | |
Emmanuel Caeymaex | Executive Vice President Immunology - Patient Value Unit Head | Profile | |
Iris LoewFriedrich | Executive Vice President Chief Medical Officer | Profile | |
JeanLuc Fleurial | Executive Vice President Chief Talent Officer, Member of the Executive Committee | Profile | |
Alexander Moscho | Executive Vice President Chief Strategy Officer, Member of the Executive Committee | Profile | |
Detlef Thielgen | CFO and Executive VP | Profile | |
Mark McDade | COO and Executive VP | Profile | |
Anna Richo | Executive VP and General Counsel | Profile | |
Ismail Kola | Chief Scientific Officer, Head of New Medicines Patient Value Unit and Executive VP | Profile | |
Kay Davies | Independent Director | Profile | |
Viviane Monges | Independent Non-Executive Director | Profile | |
Cyril Janssen | Director | Profile | |
Cedric Rijckevorsel | Director | Profile | |
Arnoud Calesberg | Non-Executive Director | Profile | |
Norman Ornstein | Non-Executive Independent Director | Profile | |
JeanPierre Kinet | Non-Executive Independent Director | Profile | |
Alice Dautry | Independent Director | Profile | |
Harriet Edelman | Non-Executive Independent Director | Profile | |
Ulf Wiinberg | Independent Director | Profile | |
Thomas McKillop | Non-Executive Independent Director | Profile | |
Pierre Gurdjian | Independent Director | Profile | |
CharlesAntoine Janssen | Non-Executive Director | Profile | |
Albrecht Graeve | Non-Executive Independent Director | Profile | |
Dirk Teuwen | VP Corporate Societal Responsibility | Profile | |
Antje Witte | VP of Investor Relations | Profile | |
France Nivelle | VP Global Communication | Profile | |
Caroline Vancoillie | Chief Functions | Profile | |
Sandrine CFA | Ex CFO | Profile | |
William Silbey | Exec Counsel | Profile | |
Evelyn Bergendal | Non-Executive Vice Chairwoman of the Board | Profile | |
Pr LowFriedrich | Chief VP | Profile | |
Kirsten LundJurgensen | Ex Solutions | Profile |
About UCB SA Management Performance
The success or failure of an entity such as UCB SA ADR often depends on how effective the management is. UCB SA management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of UCB management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the UCB management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company was incorporated in 1925 and is headquartered in Brussels, Belgium. UCB S operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 8600 people.
The data published in UCB SA's official financial statements usually reflect UCB SA's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of UCB SA ADR. For example, before you start analyzing numbers published by UCB accountants, it's critical to develop an understanding of what UCB SA's liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of UCB SA's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, UCB SA's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in UCB SA's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of UCB SA ADR. Please utilize our Beneish M Score to check the likelihood of UCB SA's management manipulating its earnings.
UCB SA Workforce Analysis
Traditionally, organizations such as UCB SA use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare UCB SA within its industry.UCB SA Manpower Efficiency
Return on UCB SA Manpower
Revenue Per Employee | 671.7K | |
Revenue Per Executive | 140.9M | |
Net Income Per Employee | 123K | |
Net Income Per Executive | 25.8M |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in UCB SA ADR. Also, note that the market value of any Company could be tightly coupled with the direction of predictive economic indicators such as signals in inflation. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Complementary Tools for UCB Pink Sheet analysis
When running UCB SA's price analysis, check to measure UCB SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy UCB SA is operating at the current time. Most of UCB SA's value examination focuses on studying past and present price action to predict the probability of UCB SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move UCB SA's price. Additionally, you may evaluate how the addition of UCB SA to your portfolios can decrease your overall portfolio volatility.
AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |